IDEXX Laboratories logo
IDEXX Laboratories IDXX
$ 560.11 -2.11%

Quarterly report 2026-Q1
added 05-05-2026

report update icon

IDEXX Laboratories Financial Statements 2011-2026 | IDXX

Annual Financial Statements IDEXX Laboratories

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

51.1 B 37.7 B 47.4 B 42.8 B 45.4 B 44.4 B 24.4 B 18 B 16.4 B 10.8 B 6.5 B 7.93 B 6.05 B 5.29 B 4.81 B

Shares

80.4 M 82.5 M 83.1 M 83.6 M 85.2 M 85.3 M 86.1 M 86.9 M 87.8 M 89.7 M 92.6 M 100 M 106 M 110 M 114 M

Historical Prices

636 457 571 511 532 520 255 211 187 145 73.2 78.4 63 46.1 42.9

Net Income

1.06 B 888 M 845 M 679 M 745 M 582 M 428 M 377 M 263 M 222 M 192 M 182 M 188 M 178 M 162 M

Revenue

4.3 B 3.9 B 3.66 B 3.37 B 3.22 B 2.71 B 2.41 B 2.21 B 1.97 B 1.78 B 1.6 B 1.49 B 1.38 B 1.29 B 1.22 B

Cost of Revenue

1.64 B 1.52 B 1.47 B 1.36 B 1.33 B 1.14 B 1.04 B 972 M 872 M 800 M 712 M 670 M 621 M 594 M 572 M

Gross Profit

2.66 B 2.38 B 2.19 B 2 B 1.89 B 1.57 B 1.37 B 1.24 B 1.1 B 975 M 890 M 816 M 756 M 699 M 647 M

Operating Income

1.36 B 1.13 B 1.1 B 899 M 932 M 695 M 553 M 491 M 413 M 350 M 300 M 260 M 267 M 263 M 236 M

Interest Expense

- - - - 29.8 M 33.1 M 31.1 M 34.7 M 37.2 M 32 M 29.2 M 15.4 M 5.39 M 3.85 M 3.55 M

EBITDA

1.51 B 1.26 B 1.21 B 1.01 B 1.04 B 791 M 641 M 575 M 496 M 428 M 377 M 319 M 321 M 315 M 284 M

Operating Expenses

1.3 B 1.25 B 1.09 B 1.11 B - - 813 M 750 M 684 M 625 M 582 M 556 M 489 M 437 M 410 M

General and Administrative Expenses

405 M 442 M 336 M 326 M 310 M 301 M 261 M 245 M 221 M 207 M 183 M 174 M 158 M 138 M 129 M

All numbers in USD currency

Quarterly Income Statement IDEXX Laboratories

2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

79.6 M 79.7 M 80.1 M 80.4 M 81.3 M 81.6 M 82.3 M 82.6 M 83.1 M 83 M 83.1 M 83.1 M 83 M 82.9 M 83.2 M 83.9 M 84.4 M 84.6 M 85.1 M 85.3 M 85.5 M 85.4 M 85.3 M 85.1 M 85.4 M 85.5 M 86.2 M 86.2 M 86.2 M 86.1 M 86.8 M 87 M 87.3 M 87.1 M 87.5 M 88 M 88.1 M - 89.9 M 89.8 M 89.9 M - 91.9 M 93.4 M 94.3 M 47.4 M 99.5 M 102 M 51.6 M - 52.4 M 53.7 M 54.6 M - 54.9 M 55.1 M 55.2 M - 56.7 M 57.3 M 57.5 M

Net Income

278 M - 275 M 294 M 243 M - 233 M 203 M 236 M - 212 M 224 M 214 M - 181 M 132 M 194 M - 175 M 203 M 204 M - 146 M 149 M 112 M 90.5 M 109 M 126 M 103 M 85.6 M 93.3 M 109 M 89.5 M 38.3 M 70.5 M 85.4 M 69 M 52.4 M 56.5 M 67.2 M 46 M 44.3 M 44.2 M 56.9 M 46.6 M 26 M 52.1 M 57.2 M 46.6 M 43.3 M 45.7 M 54 M 44.9 M 43.4 M 42.9 M 51.3 M 40.7 M 38 M 38.5 M 48.7 M 36.6 M

Revenue

1.14 B - 1.11 B 1.11 B 998 M - 976 M 1 B 964 M - 916 M 944 M 900 M - 842 M 861 M 837 M - 810 M 826 M 778 M - 722 M 638 M 626 M 605 M 605 M 620 M 576 M 549 M 545 M 581 M 538 M 506 M 492 M 509 M 462 M 443 M 448 M 467 M 418 M 400 M 406 M 413 M 382 M 352 M 384 M 390 M 360 M 354 M 338 M 353 M 332 M 320 M 315 M 336 M 323 M 307 M 301 M 318 M 293 M

Cost of Revenue

418 M - 422 M 415 M 375 M - 380 M 384 M 371 M - 368 M 371 M 357 M - 335 M 347 M 338 M - 338 M 337 M 307 M - 299 M 258 M 267 M - 260 M 262 M 244 M - 240 M 248 M 235 M - 218 M 216 M 204 M - 202 M 206 M 190 M - 182 M 181 M 167 M - 170 M 172 M 158 M - 153 M 155 M 148 M - 145 M 151 M 148 M - 142 M 144 M 138 M

Gross Profit

723 M - 683 M 695 M 623 M - 596 M 619 M 593 M - 548 M 573 M 543 M - 507 M 514 M 499 M - 473 M 489 M 471 M - 423 M 379 M 360 M 331 M 345 M 358 M 332 M 300 M 306 M 332 M 303 M 272 M 274 M 293 M 258 M 241 M 247 M 261 M 228 M 218 M 224 M 233 M 216 M 182 M 213 M 219 M 202 M 189 M 186 M 198 M 184 M 169 M 171 M 185 M 175 M 159 M 159 M 174 M 155 M

Operating Income

363 M - 355 M 373 M 317 M - 304 M 264 M 299 M - 275 M 296 M 280 M - 245 M 179 M 248 M - 226 M 259 M 248 M - 172 M 193 M 144 M 116 M 140 M 164 M 133 M 115 M 117 M 146 M 113 M 97.8 M 100 M 123 M 92.2 M 83.8 M 88.5 M 104 M 73.8 M 66.9 M 71.9 M 88.3 M 72.8 M 34.8 M 72.2 M 83.2 M 70 M 61.3 M 65.5 M 78.8 M 61.2 M 63.4 M 62.9 M 75.8 M 60.4 M 55.3 M 56.1 M 71.3 M 53.5 M

Interest Expense

- - - - - - - - 7.91 M - 8.65 M 10.5 M 13.1 M - 11 M 8.32 M 7 M - 7.13 M 7.61 M 7.58 M - 8.11 M 9.5 M 7.69 M - 7.09 M 8.19 M 8.39 M - 8.45 M 8.46 M 9.27 M - 9.76 M 9.16 M 8.59 M - 7.79 M 8.2 M 8.3 M - 7.75 M 7.26 M 6.3 M - 4.29 M 2.96 M 2.77 M - 1.46 M 1.18 M 835 K - 873 K 926 K 1.19 M - 928 K 782 K 728 K

EBITDA

400 M - - - 351 M - - - 329 M - - - 309 M - 328 M 179 M 275 M - 303 M 259 M 273 M - 243 M 240 M 168 M 116 M 205 M 207 M 154 M 115 M 180 M 187 M 134 M 97.8 M 162 M 163 M 113 M 83.8 M 146 M 142 M 92.3 M 66.9 M 123 M 121 M 89 M 34.8 M 116 M 111 M 83.4 M 61.3 M 107 M 106 M 74.7 M 63.4 M 101 M 102 M 73.1 M 55.3 M 91.5 M 94.6 M 65 M

Operating Expenses

360 M - 329 M 322 M 307 M - 292 M 355 M 294 M - - - - - - - - - - - - - - - - - - - - - 188 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

119 M - 106 M 98.7 M 91.6 M - 91.9 M 157 M 92 M - 89 M 89.7 M 70.1 M - 83.8 M 81.5 M 77.9 M - 82.1 M 73.3 M 70.8 M - 105 M 60.3 M 65.8 M - 66.3 M 60 M 60.4 M - 64 M 61.1 M 60.9 M - 57.2 M 55.5 M 52.9 M - 52.6 M 54.3 M 49.3 M - 46.2 M 44.9 M 42.6 M - 45.7 M 41.8 M 41.1 M - 38.7 M 38.9 M 41.6 M - 35.3 M 34.3 M 36.2 M - 32.5 M 33.1 M 32.6 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements IDEXX Laboratories IDXX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting IDEXX Laboratories plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Fulgent Genetics Fulgent Genetics
FLGT
$ 15.96 5.63 % $ 483 M usaUSA
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.76 1.09 % $ 177 M chinaChina
Castle Biosciences Castle Biosciences
CSTL
$ 19.83 3.07 % $ 575 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 115.62 -2.55 % $ 35.1 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
CareDx, Inc CareDx, Inc
CDNA
$ 21.82 1.77 % $ 1.16 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Lantheus Holdings Lantheus Holdings
LNTH
$ 93.06 2.26 % $ 6.28 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 424.0 -1.1 % $ 12.2 B usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 2.53 31.09 % $ 3.37 M usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 4.29 4.89 % $ 397 M usaUSA
NeoGenomics NeoGenomics
NEO
$ 8.96 -1.21 % $ 1.15 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 18.75 0.11 % $ 420 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Natera Natera
NTRA
$ 194.24 -11.64 % $ 19.1 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 177.62 -2.23 % $ 8.8 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 27.21 0.18 % $ 25.8 B niderlandNiderland
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Personalis Personalis
PSNL
$ 5.98 -0.17 % $ 534 M usaUSA
Guardant Health Guardant Health
GH
$ 95.7 3.73 % $ 12 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 5.03 -6.16 % $ 210 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 52.95 - $ 2.69 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 124.49 -0.41 % $ 10.3 B irlandaIrlanda
Illumina Illumina
ILMN
$ 141.88 2.29 % $ 22.6 B usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.95 -2.5 % $ 8.63 M usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.61 2.52 % $ 219 M irlandaIrlanda
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 56.85 -2.89 % $ 3.4 B usaUSA
Biomerica Biomerica
BMRA
$ 2.15 -2.05 % $ 4.94 M usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 465.0 -1.99 % $ 175 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 254.12 -1.52 % $ 21.1 B usaUSA
Celcuity Celcuity
CELC
$ 131.06 0.27 % $ 6.13 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Waters Corporation Waters Corporation
WAT
$ 355.13 1.32 % $ 21.1 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 9.05 -2.16 % $ 1.96 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 187.39 -1.82 % $ 20.8 B usaUSA